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Ghrelin abnormalities contribute to anorexia, inflammation,
and cardiovascular risk in hemodialysis patients, leading to
worse outcome. However, ghrelin levels are influenced by the
nutritional status of the individual. We hypothesized that the
consequences of ghrelin alterations in hemodialysis patients
are context sensitive and dependent on the presence of
protein-energy wasting (PEW). In this cross-sectional study of
217 prevalent hemodialysis patients followed for 31 months,
we measured ghrelin, leptin, PEW (subjective global
assessment), and C-reactive protein (an index of
inflammation). Compared to patients in the middle and
upper tertile of ghrelin levels, those in the lowest tertile were
older, had higher leptin levels and body mass index, and
presented an increased mortality risk that persisted after
adjustment for age, gender, and dialysis vintage. This risk
was lost after correction for comorbidities. Patients with PEW
and low ghrelin values had abnormally high C-reactive
protein and leptin by multivariate analysis of variance, and
the highest mortality risk compared to non-PEW with high
ghrelin from all-cause and cardiovascular-related mortality
(adjusted hazard ratios of 3.34 and 3.54, respectively). Low
ghrelin values in protein-energy wasted hemodialysis
patients were linked to a markedly increased cardiovascular
mortality risk. Thus, since these patients were more anorectic,
our results provide a clinical scenario where ghrelin therapies
may be particularly useful.
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The prevalence of protein-energy wasting (PEW), manifested
as a loss of muscle mass and a mismatch between energy
expenditure and intake, is high in advanced chronic kidney
disease (CKD).1–3 Like in other wasted patient groups,
anorexia is common and often linked to persistent systemic
inflammation, reduced quality of life, and increased mortal-
ity.4,5 The regulation of anorexia includes a complex
hypothalamic process in which different appetite-regulating
centers are affected not only by neuropeptides, but also by
peripheral signals from fat tissue and the gut.6–8
Ghrelin is an orexigenic peptide released primarily from
endocrine cells in the stomach, which increases appetite and
adjusts both short-term and long-term energy balance.9 The
orexigenic effects of ghrelin are mediated through the type 1a
growth hormone secretagogue receptor, leading to increased
gene expression of orexigenic neuropeptides and increased
growth hormone (GH) release.10 In advanced CKD, total
ghrelin levels are high11,12—a finding that seems counter-
intuitive given its orexigenic action and that has been
interpreted as a defense mechanism against starvation. Yet,
and despite this elevation/resistance, subcutaneous ghrelin
administration resulted in several-fold increases in plasma
ghrelin concentration followed by improvements in short-
term energy intake and energy balance in mildly to
moderately malnourished dialysis patients.13,14 Similarly, a
superagonist of GH-releasing hormone caused rapid improve-
ment of nutritional status in CKD stage 4 and 5 patients
without apparent GH deficiency.15 Furthermore, ghrelin
appears to be involved in other pathophysiological pathways
such as improvement of cardiac function,16,17 suppression of
sympathetic activity,18 inhibition of the inflammatory
response,19,20 anabolic effects on lean mass,21,22 metabolic
syndrome,23 and mediation in insulin sensitivity signaling24
or atherosclerosis.25 In CKD, all these pathways have also
been linked to PEW.1
Several studies, both in animals and humans, have
suggested that not only is ghrelin dependent on body fat
mass,26 but is also influenced by the individual’s nutritional
status; although the orexigenic effect of peripheral ghrelin
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administration differed between rats with different baseline
food intake,27 ghrelin values were markedly different among
women with anorexia nervosa and constitutionally thin
women, who display a similar low body mass index (BMI)
but no nutritional disorder.28,29 In advanced CKD, PEW is a
common problem, representing severe and complex processes
of muscle loss, poor food intake, inflammation and
cardiovascular disease (CVD)1 pathways, all of which share
intriguing links with the purported ghrelin actions discussed
above. Interestingly, the combined effect of ghrelin and
higher food intake, but not ghrelin alone, was able to enhance
skeletal muscle mitochondrial oxidative capacity and AKT
phosphorylation in rats with CKD.30 Given the interrelations
of PEW with ghrelin, we hypothesized that the implications
of low ghrelin in CKD patients are context sensitive and
dependent on the presence of PEW. With this purpose, we
assessed total ghrelin in a well-characterized cohort of 217
prevalent patients undergoing hemodialysis.
RESULTS
The study population consisted of 217 patients undergoing
hemodialysis (125 men; 57%) with a median age of 66
(25th–75th percentile 51–74) years. The patients had an
average BMI of 24.5±5.2 kg/m2. Of these patients, 55 (25%)
had diabetes, 139 (36%) had clinical signs or history of CVD,
and 102 (47%) were wasted (subjective global assessment
(SGA) 41). Patients underwent hemodialysis three times
weekly (4 to 5 h per session) using bicarbonate dialysate.
They had undergone hemodialysis for a median period of
29 months (15–58) months and the majority was anuric.
Most patients used polyamide membranes (59%), followed
by polysulfone (35%). Regarding vascular access, 58% had an
arteriovenous fistula, whereas 22 and 20% had grafts and
central dialysis catheters, respectively.
The general characteristics of the patients according to
ghrelin thirds (low third vs the other two-thirds combined)
are summarized in Table 1. We should remind the reader
that, for a correct interpretation of our results, our
definitions of low and high ghrelin correspond to the
patients’ range. Patients with low ghrelin levels were older,
had higher BMI, higher plasma levels of leptin, lower plasma
levels of adiponectin, and tended to be more often males.
Table 1 also shows the univariate associations between ghrelin
levels and selected variables as assessed by Spearman’s rank
test. Ghrelin concentration positively associated with adipo-
nectin, whereas negatively associated with age, male sex, BMI,
and leptin (as well as the leptin/BMI ratio).
Survival analysis was determined after a median follow-up
period of 31 (20–38) months. During this period, 83 (38%)
deaths occurred, of which 36 (44% of all deaths) were
because of purportedly CVD-related causes. The impact of
ghrelin levels on outcome was studied by the Kaplan–Meier
method using the high ghrelin group (middle and high thirds
combined) as the reference. Patients with low ghrelin levels
had a worse all-cause mortality (log-rank (w2) 5.50; P¼ 0.01).
Crude and adjusted Cox proportional hazard ratios (HRs) for
mortality showed that patients with low ghrelin values had a
significant crude HR (compared with patients with high
ghrelin) of 1.68 (95% confidence interval (CI) 1.08–2.60) that
persisted after adjustment of age, sex, and dialysis vintage
(HR 1.55, 95% CI 0.99–2.40), but disappeared after further
adjustment for comorbidities.
We then studied the implications of low ghrelin levels
in the context of PEW. The clinical and biochemical
Table 1 | General characteristics according to ghrelin thirds and univariate associations with serum ghrelin concentration in
217 hemodialysis patientsa
Low ghrelin (n=72) High ghrelin (n=145) P-valueb qc
Ghrelin, pg/ml 231 (173–261) 423 (367–561) — —
Age, years 69 (55–80)d 63 (50–72) 0.006 0.17**
Men, % 67e 53 0.05 —
Dialysis vintage, months 30 (15–55) 28 (14–58) 0.9 0.02
Diabetes, % 29.2 23.4 0.3 —
CVD, % 66.7 62.8 0.6 —
PEWf, % 44.4 48.3 0.6 —
BMI, kg/m2 25.6±4.8g 24.0±5.3 0.01 0.26***
Total cholesterol, mmol/l 4.3±1.1 4.4±1.0 0.7 0.09
Serum albumin, g/l 34.2±4.6 34.9±4.4 0.4 0.02
CRP, mg/l 6.5 (2.9–17.0) 7.0 (2.5–22.5) 0.9 0.07
Nt-Pro-BNP, pg/l 8.4 (3.3–21.7) 7.3 (2.8–33.9) 0.8 0.02
Adiponectin, mg/ml 19.2 (11.9–26.2) 23.9 (15.4–32.7) 0.001 0.34***
Leptin, ng/ml 19.9 (8.4–64.4) 13.4 (5.1–44.2) 0.01 0.23***
Leptin/BMI 0.81 (0.40–2.22) 0.58 (0.24–1.90) 0.02 0.20**
Abbreviations: BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; Nt-Pro-BNP, N-terminal prohormone brain natriuretic peptide; PEW, protein-energy
wasting.
aThe low ghrelin group was defined as ghrelin values below the 33rd percentile (lower third) of distribution.
bSignificantly different from the low ghrelin group if Po0.05, as assessed by Mann–Whitney U test or w2 test.
cUnivariate correlation with ghrelin concentration as assessed by Spearman’s rank test; asterisks denote statistical significance as follows: **Po0.01; ***Po0.001.
dMedian value; 25th to 75th percentile shown in parentheses (all such values).
ePrevalence, shown in percentage (all such values).
fPEW was defined as Subjective Global Assessment 41.
gAverage±s.d. (all such values).
750 Kidney International (2011) 79, 749–756
or ig ina l a r t i c l e JJ Carrero et al.: Ghrelin and mortality in wasted hemodialysis patients
characteristics of the patients according to this categorization
are detailed in Table 2. Patients with low ghrelin were older,
had higher BMI, and presented lower adiponectin. Patients
with PEW were also older and exhibited signs of inflamma-
tion (increased C-reactive protein (CRP) levels and lower
serum albumin) and elevated N-terminal prohormone brain
natriuretic peptide values. A significant ghrelin PEW
interaction was found for CRP and leptin values: patients
with both PEW and low ghrelin values exhibited the highest
CRP concentrations and the highest leptin values (Figure 1).
The latter was true even after normalization by BMI, that is,
leptin levels indexed to BMI.
Survival analysis for these four groups showed, as
expected, a negative impact of PEW but also a detrimental
impact for concurrent low ghrelin values. Thus, across the
four ghrelin-PEW categories, the percentage of deaths during
follow-up (both from all- and CVD-related causes) was
incrementally higher (Table 3). In Kaplan–Meier curves, this
group division resulted in a worse outcome because of both
all-cause (log-rank (w2) 24.61; Po0.0001) and CVD-related
(log-rank (w2) 15.55; P¼ 0.001) mortality (Figure 2). Crude
and adjusted Cox proportional HRs are depicted in Table 3,
choosing as the reference the group without PEW and
elevated ghrelin values. Regarding all-cause mortality, both
wasted groups exhibited a worse outcome in crude and
adjusted analysis, being considerably worse in magnitude for
the group of wasted patients who also had low ghrelin. The
HR of wasted patients with low ghrelin compared with
wasted patients with high ghrelin was 2.05 (95% CI
1.17–3.57), a difference that persisted after multivariate
adjustment (HR 1.96, 95% CI 1.11–3.50). Regarding CVD-
related mortality, it was only the group of patients with both
PEW and low ghrelin values who had worse outcome in both
crude and adjusted models (Table 3). The HR for CVD
Table 2 | Clinical and biochemical characteristics in 217 hemodialysis patients, according to ghrelin and nutritional statusa
Not wasted (n=115) Wasted (n=102)
High ghrelin (n=75) Low ghrelin (n=40) High ghrelin (n=70) Low ghrelin (n=32) MANOVAb
Ghrelin, pg/ml 423 (358–522)c 219.2 (138–253) 435 (382–619) 256 (212–279) —
Age, years 64 (48–73) 66 (46–79) 62 (53–71) 75 (65–81) G, W
Men, % 47d 80 46 50 0.004e
Vintage, months 28 (13–57) 34 (19–59) 29 (14–66) 22 (11–54) NS
Diabetes, % 20 27.5 27.1 31.3 NSe
CVD, % 57.3 62.5 68.5 71.8 NSe
BMI, kg/m2 24.9±5.8f 25.7±3.9 22.9±4.5 25.6±5.9 G
Serum albumin, g/l 36.5±3.9 36.0±3.3 33.2±4.3 31.9±5.1 W
Total cholesterol, mmol/l 4.5±1.1 4.4±1.0 4.2±0.9 4.2±1.2 NS
CRP, mg/l 4.1 (1.8–15.5) 5.2 (1.8–8.2) 10.0 (3.8–27.0) 12.4 (4.1–31) W, GW
Nt-Pro-BNP, pg/l 4.6 (2.2–12.9) 3.7 (1.7–17.1) 11.5 (5.2–3.5) 14.3 (3.2–3.5) W
Adiponectin, mg/ml 22.2 (14.6–29.9) 17.2 (10.6–25.7) 26.9 (15.4–37.9) 23.5 (14.3–26.7) G, W
Leptin, ng/ml 20.4 (6.0–61.4) 17.4 (7.8–44.7) 8.0 (3.6–22.5) 34.6 (8.9–91.3) GW
Leptin/BMI 0.78 (0.27–2.16) 0.74 (0.34–1.65) 0.37 (0.20–0.85) 1.25 (0.50–3.35) GW
Abbreviations: BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; MANOVA, multivariable analysis of variance; NS, nonsignificant; Nt-Pro-BNP,
N-terminal prohormone brain natriuretic peptide; PEW, protein-energy wasting.
aThe low ghrelin group was defined as ghrelin values below the 33rd percentile (lower third) of distribution, whereas PEW was defined as Subjective Global Assessment 41.
bTwo-factor MANOVA. Significant (Po0.05) effects are given for ghrelin (G), PEW (W), and the interaction ghrelin PEW (GW).
cMedian value; 25th to 75th percentile shown in parentheses (all such values).
dPrevalence, shown in percentage (all such values).
eAssessed by w2 test.
fAverage±s.d. (all such values).
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Figure 1 |PEW modifies the cross-sectional association of
ghrelin with circulating CRP and leptin. Levels of (a) C-reactive
protein (CRP) and (b) leptin among ghrelin and wasting categories
cross-classified in 217 prevalent patients undergoing hemodialysis.
Data are presented as average values with error bars depicting 95%
confidence intervals. Multivariable analysis of variance (ANOVA)
showed a significant ghrelinwasting interaction for both CRP and
leptin values. PEW, protein-energy wasting.
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mortality of wasted patients with low ghrelin compared with
wasted patients with high ghrelin was 2.63 (95% CI
1.15–5.99), a difference that persisted after multivariate
adjustment (HR 2.78, 95% CI 1.18–6.52). As a sensitivity
analysis, results were confirmed by excluding patients within
the middle third of ghrelin, and comparing bottom vs top
third only; HRs continued being statistically significant in
both uni- and multi-variate models (data not shown). The
causes of death are detailed in Table 4.
DISCUSSION
This study reports, for the first time in CKD and we believe
in any patient group, an increased mortality risk for patients
with low ghrelin values. Although this effect was modest and
did not stand full adjustment for confounders, the prognostic
value of low ghrelin on outcome seemed magnified in the
context of PEW. Thus, wasted patients with low ghrelin
concentration presented the highest mortality risk, especially
cardiovascular-related mortality. This group of patients
showed at the same time abnormally elevated serum CRP
and leptin values, forming altogether a pattern of concomi-
tant conditions that seem to fit with the purported anti-
inflammatory,19,20 cardioprotective,16,17 and orexigenic14
effects attributed to ghrelin administration. Our study
therefore identifies a group of dialysis patients who could,
at least in theory, benefit from ghrelin treatment.13,14
To the best of our knowledge, the only available study
linking ghrelin with mortality comes from an animal study
where ghrelin injection early after myocardial infarction
prevented an increase in cardiac sympathetic tone and
reduced mortality (survival rate 77% in the treated group
vs 39% in the placebo).31 Our study shows that in dialysis
patients low ghrelin levels were associated with an increased
mortality risk, but that this increased risk was lost after
correction for cardiovascular comorbidities, suggesting that
cardiovascular comorbidities may, at least in part, operate
within the same causal pathway of ghrelin and mortality.16,17
It is tempting to speculate that the uremic phenotype with
markedly increased prevalence of anorexia, PEW, inflamma-
tion, and CVD may magnify these interactions. In agreement
with previous studies indicating that ghrelin is influenced by
Table 3 | Crude and adjusted all-cause and CVD-related mortality according to ghrelin and wasting groupsa
Non-wasted, low ghrelin Wasted, high ghrelin Wasted, low ghrelin
Model Covariates HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
All-cause mortality
1 Crude 1.51 (0.72–3.06) 0.2 2.09 (1.17–3.74) 0.01 4.33 (2.30–8.16) o0.0001
2 1+age, sex, and vintageb 1.55 (0.74–3.18) 0.2 2.37 (1.31–4.32) 0.004 3.53 (1.84–6.74) 0.0002
3 2+diabetes and CVD 1.37 (0.64–2.82) 0.4 2.24 (1.24–4.16) 0.007 3.34 (1.74–6.41) 0.0003
Cardiovascular-related mortality
1 Crude 0.92 (0.25–2.85) 0.9 1.61 (0.68–3.94) 0.3 4.36 (1.79–10.86) 0.001
2 1+age, sex, and vintageb 0.94 (0.25–2.92) 0.9 1.77 (0.73–4.44) 0.2 3.88 (1.56–9.50) 0.003
3 2+diabetes and CVD 0.78 (0.21–2.44) 0.7 1.64 (0.68–4.08) 0.3 3.54 (1.40–8.91) 0.008
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.
aIndicated are univariate and multivariate HRs and 95% CIs for all-cause and CVD mortality. The group of patients who were non-wasted (defined as Subjective Global
Assessment 41) and had high ghrelin (grouping middle and high thirds of serum ghrelin together) was used as a reference.
bAge was categorized according to o45, 45–65, and 465 years, selecting the youngest group as the reference; dialysis vintage was dichotomized to the round
approximation of the median value (2 years), using the shorter vintage as the reference category; female sex, the absence of diabetes, and of CVD were considered reference
categories.
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Figure 2 |PEW modifies the impact of low ghrelin values on
mortality. Kaplan–Meier (a) all-cause and (b) cardiovascular-
related mortality curves among ghrelin and wasting categories
cross-classified in 217 prevalent patients undergoing
hemodialysis. PEW, protein-energy wasting.
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the individual’s nutritional status,27–29 our results also
indicate that the increased mortality risk associated with a
state of PEW is further aggravated by low ghrelin values.
Indeed, this group of individuals showed the highest
mortality risk, especially because of cardiovascular-related
causes, which agrees with the present understanding of
ghrelin’s implications in cardiovascular physiology. Available
literature provides some clues on the plausible mechanisms
linking ghrelin with cardiovascular disease: indeed, in
experimental models ghrelin has been shown to inhibit
cardiomyocyte cell death,32 improve left ventricular func-
tion,17 suppress cardiac sympathetic activity, decrease plasma
norepinephrine, and prevent early left ventricular remodel-
ing.33 In humans, a correlation between ghrelin levels and
blood pressure has been observed,24 and infusion of a ghrelin
agonist decreases blood pressure and heart rate34 and
recovers ventricular function.16 In dialysis patients, ghrelin
was found to be linked to coronary microvascular, endothe-
lial,35 and left ventricular36 dysfunction. Interestingly, in the
absence of PEW, low ghrelin did not exert any detrimental
effect on outcome.
As expected, we found a negative correlation between
leptin and ghrelin, because while ghrelin stimulates, leptin
inhibits food intake, competing for the same hypothalamic
targets. At a neuronal level, ghrelin-induced activation of
neuropeptide Y neurons is suppressed by subsequent
administration of leptin.37 Ghrelin and leptin thus recipro-
cally regulate neuropeptide Y neurons, and the balance of
ghrelin and leptin levels seems critical for energy homeostasis
regulation. However, the precise nature of the interaction
between ghrelin and leptin and the underlying signaling
mechanisms in neuropeptide Y neurons are largely unknown.
In CKD, clinical studies have yet not been able to
demonstrate a role of hyperleptinemia in anorexia or PEW,
and a state of leptin resistance has been proposed.38 Because
CRP may directly block the effects of leptin upon satiety
and weight reduction,39 systemic uremic inflammation may
contribute to leptin resistance. It is plausible (although not
yet demonstrated) that the regulation of ghrelin metabolism
may add to this complex scenario. The wasted patients in our
study with low ghrelin values presented abnormally high
leptin concentrations (even after correction for BMI),
providing a scenario with a clear balance shift toward a
pro-anorectic situation. This group of patients was also the
most inflamed and presented the worst outcome. Ghrelin
administration has been shown to inhibit proinflammatory
responses and nuclear factor-kB activation in human
endothelial cells, monocytes, and T cells.19,20 Also, in a rat
model of CKD, 14 days of ghrelin infusion resulted in
improved lean body mass and less inflammation.21 In
agreement with this, the concurrent presence of low ghrelin
and PEW in our study significantly increased the levels of
CRP, which is in turn a well-recognized mortality risk
marker.40
Given the extensive history of negative randomized
controlled trials in the dialysis population, it is exciting that
two small randomized controlled trials with ghrelin infusion
therapy show encouraging results in improving food intake
in malnourished dialysis patients.13,14 As ghrelin may not
only reduce systemic inflammation19,20 but also improve
cardiac performance,16,17 our study identifies a specific group
of wasted, inflamed, and ghrelin-deficient patients at
increased (cardiovascular) mortality risk who potentially
could benefit from this therapy. We should bear in mind,
however, that the evidence so far in CKD is based on small-
size short-duration trials and further studies regarding safety,
way of administration, and side effects are still needed before
its use could be recommended.41
Several important limitations of this study should be
noted, and taking these into consideration we believe that our
Table 4 | Individual causes of death according to ghrelin and nutritional statusa
Not wasted Wasted
High ghrelin (n=75) Low ghrelin (n=40) High ghrelin (n=70) Low ghrelin (n=32)
Cardiac arrest/sudden death 4 1 2 2
Myocardial infarction 4 — 3 6
Cerebrovascular accident — — 3 1
Other causes of cardiac death 1 3 3 2
Hemorrhage 1 — 1 —
Pulmonary edema — — 1 —
Malignancy 1 1 — 2
Infection/septicemia 1 3 7 2
ESRD treatment withdrawn 3 2 2 1
Patient refused further RRT — — 2 —
Cachexia 1 — 2 —
Other — — 2 1
Uncertain/not determined 2 3 3 4
All deathsb, n (%) 18 (24%) 13 (32%) 31 (44%) 21 (65%)
CVD deathsb, n (%) 9 (12%) 4 (10%) 11 (17%) 11 (35%)
Abbreviations: CVD, cardiovascular disease; ESRD, end-stage renal disease; RRT; renal replacement therapy.
aIndicated are the causes and number of deaths (n) in each category.
bIndicated are the number of deaths and percentage, expressed as a proportion of the total number of patients in the group. The proportion of deaths was incrementally
higher across the group as assessed by w2 test (P=0.004 for all deaths and P=0.03 for CVD deaths).
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results are only hypothesis generating. First, because it is a
cross-sectional design, the present analysis is limited in its
ability to establish causal relationships. Second, as our cohort
was relatively small and consisted of prevalent patients (a
group of survivors), our findings need confirmation in larger
as well as incident patient cohorts. Third, samples were taken
in non-fasting conditions, 1–3 h after a meal. Although this
may have affected ghrelin values, we should bear in mind that
the parameters to which ghrelin is related to in this study
(PEW, leptin, CRP, and outcome) are not affected by the
postprandial state. Additionally, total ghrelin levels decrease
very modestly after a standardized meal in dialysis patients,
as opposed to healthy individuals.42 What factors trigger
postprandial ghrelin suppression are presently unknown, but
postprandial suppression of ghrelin in healthy volunteers
occurs independent from the previous day’s intake and does
not relate to subsequent food intake.43 Also, a high-protein
diet reduced food intake in healthy individuals despite
compensatory changes in ghrelin concentration.44 One more
consideration is that because fatal cardiovascular events were
extracted from patient records and not always confirmed by
autopsies, the true prevalence of cardiac end points could not
be established, being possibly higher. Finally, our analysis
relies on total ghrelin concentration, not differentiating
between the different ghrelin isoforms. It would have been
desirable to measure acylated ghrelin in this study, but at the
time of data collection, little was known about ghrelin
isoforms, and samples were not pretreated with protease
inhibitors. Finally, PEW was defined on the basis of SGA,
which is a widely used nutritional assessment in dialysis
patients but not the only one. Thus, we cannot exclude that
results may differ when using other methodology to define
PEW. Notwithstanding these limitations, the availability of
extensive data with detailed characterization of a wide range
of important risk factors and end points, including
inflammatory biomarkers, comorbidities, and outcome,
strengthens the study.
In conclusion, we report that low ghrelin values in wasted
hemodialysis patients are linked to a markedly increased
mortality risk, especially because of cardiovascular causes. As
these patients exhibited a more anorectic phenotype
(increased inflammation and serum leptin), our results
provide a scenario where ghrelin therapies may be particu-
larly useful. Whether ghrelin administration could directly,
or indirectly through its beneficial metabolic effects, improve
long-term outcomes in this patient population is a hypoth-
esis that deserves further attention.
MATERIALS AND METHODS
Study population
The study was performed at five dialysis units in Stockholm, and
one at the Uppsala Academic Hospital in Uppsala, Sweden. This is a
post hoc analysis of data arising from a cross-sectional study
originally aiming at investigating the variability of inflammatory
markers in patients undergoing hemodialysis. The protocol has been
previously described in more detail and patient recruitment took
place between October 2003 through March 2004.4 Out of the 224
prevalent patients included in the study and followed for assessment
of overall and cardiovascular mortality, ghrelin data could only be
measured in 217 patients because of lack of stored plasma for the
missing seven patients. A single clinician, who extracted data
pertaining to the underlying CKD, CVD history, and diabetes,
reviewed each patient’s medical chart. Survival was determined after
a mean follow-up of 31 (20–38) months, with no loss of follow-up of
any patient. Cardiovascular mortality was defined as death resulting
from coronary heart disease, sudden death, stroke, or complicated
peripheral vascular disease. The study protocol was approved by the
ethics committee of Karolinska Institute at Huddinge University
Hospital, Stockholm, Sweden, and informed consent was obtained
from each patient.
Nutritional status
BMI was determined on a dialysis day. A translation into
Swedish45,46 of the SGA questionnaire47 was used to evaluate the
overall nutritional status. In the validation of SGA measurements in
dialysis patients against total-body nitrogen level, Cooper et al.48
showed that SGA differentiated malnourished patients from those
with normal nutrition, but failed to reliably distinguish the degree
of malnutrition. For that reason, we dichotomized the variable
into presence (SGA 41) or absence (SGA 1) of wasting signs. SGA
measurements are used in this study as a surrogate of PEW.
Laboratory analysis
Non-fasting blood samples were collected before the dialysis session.
The plasma was separated within 30 min and samples were kept
frozen at 70 1C if not analyzed immediately. Concentrations of
high-sensitivity CRP, serum albumin (bromcresol purple), and total
cholesterol concentration were determined using routine methods at
the Department of Laboratory Medicine, Karolinska University
Hospital, Huddinge, Sweden. N-terminal prohormone brain
natriuretic peptide was measured by an automated immulite
analyzer (Siemens Healthcare Diagnostics, Los Angeles, CA). Both
plasma leptin (Linco Research, St Charles, MO) and plasma total
ghrelin (Phoenix Pharmaceuticals, Belmont, CA) were measured by
radioimmunoassay methods, using commercial assays and accord-
ing to the manufacturer’s instructions.
Statistical analysis
Normally distributed variables were expressed as mean±s.d., and
non-normally distributed variables were expressed as median and
interquartile range (25th–75th percentiles). Categorical data were
presented as percentage values. Comparisons between two groups
were assessed with Mann–Whitney or w2 tests. Spearman’s rank
correlation (r) was used to determine correlations of ghrelin with
other variables. As there is no clinically established cutoff value for
low ghrelin levels, the lower third of ghrelin distribution in our
patient population was considered as a low concentration. A two-
factor multivariable analysis of variance with Wilk’s l was used to
measure the degree of correlation between the variables. The model
included a test for the effect of order. The general linear model
procedure with least-squares means was used to identify significant
interactions between factors. The w2 test was used for categorical
variables. Survival analyses used the Kaplan–Meier survival curve
and the Cox proportional hazards model. The univariate and
multivariate Cox regression analysis are presented as HR (95% CI).
All statistical analyses were performed with SAS statistical software
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(Version 9.2; SAS Institute, Cary, NC), with statistical significance
set at the level of Po0.05.
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